【摘要】：目的:探討5-氟尿嘧啶(5-FU)血藥濃度與替吉奧聯(lián)合紫杉醇治療晚期胃癌患者的療效和安全性之間的關(guān)系。方法:選取78例接受替吉奧聯(lián)合紫杉醇治療的晚期胃癌患者,于每一個化療周期監(jiān)測5-FU血藥濃度。分析5-FU血藥濃度與療效和安全性的關(guān)系。結(jié)果:78例患者不同化療周期5-FU的中位血藥濃度為150μg/L,據(jù)此將患者分為A組(≥150μg/L,40例)和B組(150μg/L,38例)。A組有效率及疾病控制率均高于B組(50.0%vs 18.4%,82.5%vs 65.8%,P均0.05)。A組骨髓抑制及口腔炎較B組嚴重(P均0.05);但2組間惡心、嘔吐及腹瀉的嚴重程度差異無統(tǒng)計學意義(P均0.05)。結(jié)論:5-FU血藥濃度≥150μg/L的晚期胃癌患者采用替吉奧聯(lián)合紫杉醇治療有更好的生存獲益,但會增加骨髓抑制及口腔炎等不良反應(yīng)的嚴重程度。
[Abstract]:Aim: to investigate the relationship between the serum concentration of 5 fluorouracil (5-FU) and the efficacy and safety of tigor combined with paclitaxel in the treatment of advanced gastric cancer. Methods: 78 patients with advanced gastric cancer treated with teguir combined with paclitaxel were selected to monitor the serum concentration of 5-FU in each chemotherapy cycle. To analyze the relationship between serum concentration of 5-FU and efficacy and safety. Results the median blood concentration of 5-FU in 78 patients with different chemotherapy cycles was 150 渭 g / L, according to which the patients were divided into two groups: group A (40 cases 鈮，

本文編號：2158875